ResMed Inc reported record revenue and income for the quarter ended December 31, 2012, driven by the ongoing shift to higher value flow generators and strong sales of CPAP accessory items.
Revenue for the quarter ended December 31, 2012 was $376.5 million, a 13% increase over the quarter ended December 31, 2011, according to ResMed.
“We had a solid quarter across the board,” said Peter C. Farrell, PhD, chairman and CEO. “There was also a continuing shift to higher value flow generators, like S9 Autoset and S9 bilevels, and mask and accessory sales remained strong.”
Looking ahead, Farrell believes the data requirements of the insurance community present opportunity for ResMed.
“We believe we are in the early stages of an exciting market dynamic for sleep-disordered breathing (SDB), which we have been pioneering for many years, by offering full solutions to therapy providers and critical information for the reimbursement community,” he said. “By providing valuable clinical and economic data to payors, we strive to help them more fully appreciate SDB therapy’s positive effect on health and cost benefit outcomes.”
